

Date: 29th April, 2025

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
BSE Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir / Madam,

Sub: Alembic Pharmaceuticals Limited receives Establishment Inspection Report (EIR) for its Oncology (Injectable and Oral Solid) Formulation Facility (F-2) at Panelav.

Ref.: Our earlier intimation dated 9th October, 2024 - Successful completion of USFDA inspection at Alembic Pharmaceuticals Limited' Oncology (Injectable and Oral Solid) Formulation Facility (F-2) at Panelav.

We are pleased to inform the exchanges that the Company has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for the inspection carried out by them at our Oncology Formulation Facility Injectable and Oral Solid) (F-2) at Panelav from 7th October, 2024 to 8th October, 2024.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123